Figure1

18/01/2026, the research team led by the University of Hong Kong, n collaboration with researchers from the Shenzhen Bay Laboratory and Tsinghua University, developed the first targeted epigenetic regulator inhibitors, opening a new avenue for lung cancer treatment. Dr. Jinzhao Liu is the co-first author of this groundbreaking study. Congratulations!

{"ARInfo":{"IsUseAR":false},"Version":"1.0.0","MakeupInfo":{"IsUseMakeup":false},"FaceliftInfo":{"IsChangeEyeLift":false,"IsChangeFacelift":false,"IsChangePostureLift":false,"IsChangeNose":false,"IsChangeFaceChin":false,"IsChangeMouth":false,"IsChangeThinFace":false},"BeautyInfo":{"SwitchMedicatedAcne":false,"IsAIBeauty":false,"IsBrightEyes":false,"IsSharpen":false,"IsOldBeauty":false,"IsReduceBlackEyes":false},"HandlerInfo":{"AppName":2},"FilterInfo":{"IsUseFilter":false}}

12/01/2026, Dr. Wanwan Chang from Macau University of Science and Technology joins our lab as a post-doctoral fellow. Warm welcome!

webwxgetmsgimg

13/01/2026, Prof. Molly Shoichet from University of Toronto was invited by the Department of Pharmacology & Pharmacy and Dr. Li Dak-Sum Research Centre, HKU to give a seminar on the topic of Lemons to Lemonade: a new twist on drug-rich nanoparticles.

webwxgetmsgimg (3)

12/01/2026, Prof. Li Tang from École polytechnique fédérale de Lausanne (EPFL) was invited by the Department of Pharmacology & Pharmacy and Dr. Li Dak-Sum Research Centre, HKU to give a seminar on the topic of Multidimensional immunoengineering approaches to enhance cancer immunotherapy: from bench to bedside and back.